Skip to main content
Erschienen in: Journal of Endocrinological Investigation 12/2017

01.12.2017 | Review

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis

verfasst von: A. L. L. Rocha, L. C. Faria, T. C. M. Guimarães, G. V. Moreira, A. L. Cândido, C. A. Couto, F. M. Reis

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Non-alcoholic fatty liver disease (NAFLD) is an insidious pathologic condition that can manifest from simple steatosis to steatohepatitis (NASH) with potential progression to cirrhosis. Like the polycystic ovary syndrome (PCOS), NAFLD is associated with obesity, diabetes mellitus, insulin resistance and metabolic syndrome. PCOS women have an increased risk of NAFLD, but it is debatable which features of PCOS, either specific (androgen excess) or unspecific (metabolic derangements) affect the NAFLD risk.

Methods

We performed a systematic review and meta-analysis of studies that addressed the association of PCOS and NAFLD. We selected 17 studies published between 2007 and 2017 that included 2734 PCOS patients and 2561 controls of similar age and body mass index (BMI).

Results

PCOS patients have increased prevalence of NAFLD (odds ratio 2.54, 95% confidence interval 2.19–2.95). PCOS women with hyperandrogenism (classic phenotype) have a higher prevalence of NAFLD compared to women with PCOS without hyperandrogenism, even after correction for confounding variables. Among women with PCOS, those with NAFLD have higher serum total testosterone (mean difference 0.40 nmol/L, 95% CI 0.29–0.50 nmol/L) and free androgen index (mean difference 4.46, 95% CI 3.53–5.39) than those without NAFLD. The studies that used multivariate analysis controlling for age, BMI, triglycerides, and insulin resistance index confirmed that serum androgens are independent predictors of NAFLD in women with PCOS.

Conclusion

The prevalence of NAFLD is increased in women with PCOS and the presence of NAFLD is associated with high serum androgen levels, in addition to obesity and insulin resistance.
Literatur
6.
Zurück zum Zitat Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F (2005) Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:1578–1582. doi:10.1210/jc.2004-1024 CrossRefPubMed Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F (2005) Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:1578–1582. doi:10.​1210/​jc.​2004-1024 CrossRefPubMed
11.
Zurück zum Zitat Federico A, D’Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R (2010) Fat: a matter of disturbance for the immune system. World J Gastroenterol 16:4762–4772CrossRefPubMedPubMedCentral Federico A, D’Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R (2010) Fat: a matter of disturbance for the immune system. World J Gastroenterol 16:4762–4772CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609. doi:10.1053/j.gastro.2012.04.001 CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609. doi:10.​1053/​j.​gastro.​2012.​04.​001 CrossRefPubMed
16.
17.
Zurück zum Zitat Yang PM, Huang GT, Lin JT, Sheu JC, Lai MY, Su IJ, Hsu HC, Chen DS, Wang TH, Sung JL (1988) Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study. Taiwan Yi Xue Hui Za Zhi 87:966–977PubMed Yang PM, Huang GT, Lin JT, Sheu JC, Lai MY, Su IJ, Hsu HC, Chen DS, Wang TH, Sung JL (1988) Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study. Taiwan Yi Xue Hui Za Zhi 87:966–977PubMed
19.
Zurück zum Zitat Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219–227. doi:10.1530/rep-14-0435 CrossRefPubMed Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219–227. doi:10.​1530/​rep-14-0435 CrossRefPubMed
22.
Zurück zum Zitat Durmus U, Duran C, Ecirli S (2017) Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 40:487–497. doi:10.1007/s40618-016-0582-x CrossRefPubMed Durmus U, Duran C, Ecirli S (2017) Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. J Endocrinol Invest 40:487–497. doi:10.​1007/​s40618-016-0582-x CrossRefPubMed
23.
Zurück zum Zitat Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of intervention. Version 5.1.0. The Cochrane Collaboration (updated March 2011) Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of intervention. Version 5.1.0. The Cochrane Collaboration (updated March 2011)
25.
Zurück zum Zitat Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA (2015) Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 52:117–123. doi:10.1590/S0004-28032015000200008 CrossRefPubMed Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA (2015) Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 52:117–123. doi:10.​1590/​S0004-2803201500020000​8 CrossRefPubMed
26.
Zurück zum Zitat Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9:402–409PubMed Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9:402–409PubMed
27.
28.
Zurück zum Zitat Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412–417. doi:10.1016/j.jhep.2007.04.012 CrossRefPubMed Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412–417. doi:10.​1016/​j.​jhep.​2007.​04.​012 CrossRefPubMed
29.
30.
Zurück zum Zitat Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 95:3332–3341. doi:10.1210/jc.2009-2698 CrossRefPubMed Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 95:3332–3341. doi:10.​1210/​jc.​2009-2698 CrossRefPubMed
31.
Zurück zum Zitat Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I (2010) Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25:212–220. doi:10.1093/humrep/dep380 CrossRefPubMed Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I (2010) Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25:212–220. doi:10.​1093/​humrep/​dep380 CrossRefPubMed
33.
Zurück zum Zitat Zueff LF, Martins WP, Vieira CS, Ferriani RA (2012) Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 39:341–347. doi:10.1002/uog.10084 CrossRefPubMed Zueff LF, Martins WP, Vieira CS, Ferriani RA (2012) Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 39:341–347. doi:10.​1002/​uog.​10084 CrossRefPubMed
34.
Zurück zum Zitat Zheng RH, Ding CF (2008) Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi 43:98–101PubMed Zheng RH, Ding CF (2008) Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi 43:98–101PubMed
35.
Zurück zum Zitat Qu ZY, Shi YH, Zhao DN, Jiang JJ, Ma ZX, Chen ZJ (2010) Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 90:2036–2039PubMed Qu ZY, Shi YH, Zhao DN, Jiang JJ, Ma ZX, Chen ZJ (2010) Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 90:2036–2039PubMed
36.
Zurück zum Zitat Polyzos SA, Goulis DG, Kountouras J, Mintziori G, Chatzis P, Papadakis E, Katsikis I, Panidis D (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones (Athens) 13:519–531. doi:10.14310/horm.2002.1493 Polyzos SA, Goulis DG, Kountouras J, Mintziori G, Chatzis P, Papadakis E, Katsikis I, Panidis D (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones (Athens) 13:519–531. doi:10.​14310/​horm.​2002.​1493
37.
Zurück zum Zitat Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D (2016) Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 31:1347–1353. doi:10.1093/humrep/dew076 CrossRefPubMed Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D (2016) Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 31:1347–1353. doi:10.​1093/​humrep/​dew076 CrossRefPubMed
39.
Zurück zum Zitat Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, Kuliczkowska-Płaksej J, Łaczmański Ł, Zaleska-Dorobisz U, Milewicz A (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome—Clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynologia Polska 65:416–421. doi:10.5603/EP.2014.0058 CrossRefPubMed Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, Kuliczkowska-Płaksej J, Łaczmański Ł, Zaleska-Dorobisz U, Milewicz A (2014) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome—Clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynologia Polska 65:416–421. doi:10.​5603/​EP.​2014.​0058 CrossRefPubMed
40.
Zurück zum Zitat Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R (2016) Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenterol Hepatol 31:980–987. doi:10.1111/jgh.13241 CrossRefPubMed Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R (2016) Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenterol Hepatol 31:980–987. doi:10.​1111/​jgh.​13241 CrossRefPubMed
41.
Zurück zum Zitat Srinivas-Prasad RH, Balakrishna BV, Kudva N, Sandhya H, Ramakrishna P (2014) Incidence of non-alcoholic hepatic fatty infiltration in women with polycystic ovary syndrome. J Evid Med Healthc 1:867–875 Srinivas-Prasad RH, Balakrishna BV, Kudva N, Sandhya H, Ramakrishna P (2014) Incidence of non-alcoholic hepatic fatty infiltration in women with polycystic ovary syndrome. J Evid Med Healthc 1:867–875
42.
Zurück zum Zitat Tarantino G, Di Somma C, Pizza G, Brancato V, Nedi V, Valentino R, Orio F, Pivonello C, Colao A, Savastano S (2013) Polycystic ovary syndrome and hepatic steatosis: could low-grade chronic inflammation be mediated by the spleen? Eur J Inflamm 11:179–191CrossRef Tarantino G, Di Somma C, Pizza G, Brancato V, Nedi V, Valentino R, Orio F, Pivonello C, Colao A, Savastano S (2013) Polycystic ovary syndrome and hepatic steatosis: could low-grade chronic inflammation be mediated by the spleen? Eur J Inflamm 11:179–191CrossRef
43.
Zurück zum Zitat Jie C, Chunhua W, Yi Z, Yuying W, Wendi X, Tzuchun L, Shengxian L, Lihua W, Jun Z, Yun S, Wei L, Tao T (2017) High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. Int J Obes (Lond). doi:10.1038/ijo.2017.116 Jie C, Chunhua W, Yi Z, Yuying W, Wendi X, Tzuchun L, Shengxian L, Lihua W, Jun Z, Yun S, Wei L, Tao T (2017) High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. Int J Obes (Lond). doi:10.​1038/​ijo.​2017.​116
44.
Zurück zum Zitat Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM (2017) Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45:1403–1412. doi:10.1111/apt.14058 CrossRefPubMed Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM (2017) Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45:1403–1412. doi:10.​1111/​apt.​14058 CrossRefPubMed
45.
Zurück zum Zitat Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD (2010) Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26:39–46. doi:10.3109/09513590903184084 CrossRefPubMed Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD (2010) Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26:39–46. doi:10.​3109/​0951359090318408​4 CrossRefPubMed
46.
Zurück zum Zitat Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ (2012) Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97:3709–3716. doi:10.1210/jc.2012-1382 CrossRefPubMed Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ (2012) Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97:3709–3716. doi:10.​1210/​jc.​2012-1382 CrossRefPubMed
47.
Zurück zum Zitat Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E (2009) In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 8:199–206CrossRef Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E (2009) In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 8:199–206CrossRef
48.
Zurück zum Zitat Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98:1254–1263. doi:10.1210/jc.2012-3698 CrossRefPubMed Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98:1254–1263. doi:10.​1210/​jc.​2012-3698 CrossRefPubMed
50.
Zurück zum Zitat Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935. doi:10.1210/jc.2004-1045 CrossRefPubMed Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935. doi:10.​1210/​jc.​2004-1045 CrossRefPubMed
51.
Zurück zum Zitat Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG (2015) Excess metabolic and cardiovascular risk is not manifested in all phenotypes of polycystic ovary syndrome: implications for diagnosis and treatment. Curr Vasc Pharmacol 13:788–800CrossRefPubMed Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG (2015) Excess metabolic and cardiovascular risk is not manifested in all phenotypes of polycystic ovary syndrome: implications for diagnosis and treatment. Curr Vasc Pharmacol 13:788–800CrossRefPubMed
52.
Zurück zum Zitat Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL (2014) A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 80:843–849. doi:10.1111/cen.12258 CrossRef Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL (2014) A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 80:843–849. doi:10.​1111/​cen.​12258 CrossRef
53.
Zurück zum Zitat Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A (2010) Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95:343–348. doi:10.1210/jc.2009-1834 CrossRefPubMed Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A (2010) Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95:343–348. doi:10.​1210/​jc.​2009-1834 CrossRefPubMed
55.
Zurück zum Zitat Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–378. doi:10.1053/j.gastro.2015.04.005 CrossRefPubMed Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–378. doi:10.​1053/​j.​gastro.​2015.​04.​005 CrossRefPubMed
56.
Zurück zum Zitat Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL (2014) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 81:523–528. doi:10.1111/cen.12369 CrossRef Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL (2014) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 81:523–528. doi:10.​1111/​cen.​12369 CrossRef
57.
Zurück zum Zitat Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Legro RS (2011) Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:E1645–1649. doi:10.1210/jc.2011-1093 CrossRefPubMedPubMedCentral Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Legro RS (2011) Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:E1645–1649. doi:10.​1210/​jc.​2011-1093 CrossRefPubMedPubMedCentral
Metadaten
Titel
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis
verfasst von
A. L. L. Rocha
L. C. Faria
T. C. M. Guimarães
G. V. Moreira
A. L. Cândido
C. A. Couto
F. M. Reis
Publikationsdatum
01.12.2017
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 12/2017
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-017-0708-9

Weitere Artikel der Ausgabe 12/2017

Journal of Endocrinological Investigation 12/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.